Tasso+ allows home blood collection for testosterone testing. Learn how sample limits, laboratory methods and clinical guidance shape interpretation.
In its October 17, 2026 report, Business Insider described men using the Tasso+ blood collection device at home for laboratory testosterone testing.
This article is for informational purposes and is not medical advice. A qualified clinician should assess individual symptoms, interpret results and make decisions about diagnosis or treatment.
The practical change is where blood collection happens. In the example described by Business Insider, a user attached the quarter-sized Tasso+ device to his upper arm and collected blood in about five minutes. The sample was then mailed to a laboratory for analysis.
That distinction matters: five minutes refers to collection in that example, not the time needed to receive a testosterone result. Tasso+ obtains a sample rather than measuring testosterone inside the device. Calling it an at-home test can blur the difference between collecting blood and analyzing it.
According to the report, Tasso+ collects capillary blood from the skin rather than venous blood obtained through a conventional blood draw. Its convenience is practical. A morning sample can be collected at home instead of requiring travel to a laboratory for collection.
For someone researching testosterone testing, this changes the logistics around obtaining a sample. The laboratory still performs the measurement. The resulting number then needs interpretation within the clinical question that prompted testing.
Business Insider names Hims & Hers, Balance My Hormones and Maximus Health as services offering Tasso+-based testosterone testing. It lists Maximus’ kit at $99. That is a reported price for one service’s kit, not a universal price for testing with the collection device.
The report also describes Rythm Health’s $79 monthly health check using Tasso+ collection. Results are provided through an app in days. Business Insider describes that panel as including testosterone alongside other hormone and metabolic markers.
These examples show that the collection device sits within a larger testing service. A kit price or subscription describes an offering. It does not by itself explain which measurement will answer a particular medical question.
Business Insider also reports that Tasso+ received FDA clearance in 2022 as a Class II medical device. That is a separate fact from the availability and pricing of the testing packages described in the story.
The relevant diagnostic framework comes from the Endocrine Society’s guidance on male hypogonadism. It calls for compatible symptoms or signs together with unequivocally and consistently low testosterone. A home collection option does not introduce a different definition of testosterone deficiency.
The guidance brings several elements together:
An assay is the laboratory method used to make the measurement. Collection and measurement therefore answer different questions: how was the blood obtained, and how was testosterone measured in that blood? Both are relevant when a result may inform a medical decision.
The Endocrine Society source also notes that testosterone can vary from day to day. Food intake can suppress levels. These are reasons to interpret the circumstances of a blood draw rather than treating a single value as a complete account of someone’s hormone health.
Testostra’s explanation of the context behind morning bloodwork provides related background. The point is not that home collection removes the importance of preparation. It makes the collection location more flexible while leaving the clinical framework intact.
Repeat testing has a specific diagnostic purpose: confirming whether a low finding is consistent. It is not simply an invitation to collect hormone numbers indefinitely. Our discussion of why one testosterone result needs context explains that distinction further.
The central evidence here is a news report about access and use. It is not a clinical trial establishing diagnostic accuracy in a defined group of men. Its examples describe people using a collection method rather than demonstrating a new physiological finding.
Business Insider reports that Tasso+ collection is slower than venipuncture and produces less blood. That smaller volume limits how many tests can be run from a collection. Convenience at home should therefore be distinguished from collection speed or the breadth of a laboratory panel.
The report says the device performs about as well as a traditional draw for much routine bloodwork. It also describes unreliable performance for some measurements, including potassium and certain proteins related to Alzheimer’s disease. Those examples make measurement-specific performance important rather than supporting a single accuracy claim for all blood tests.
The report does not establish that Tasso+ testosterone results are inaccurate. It presents testosterone testing as a use offered by services. However, it does not provide assay-by-assay validation details showing how each service’s testosterone measurement performs with that sample type.
FDA clearance for the collection device should not be read as proof that every possible measurement is interchangeable with a venous test. The relevant question is narrower: what has the particular service and laboratory validated for the sample being collected and the test being performed?
There is also a distinction between knowing that a panel contains testosterone and knowing its full contents. Business Insider does not list every marker in the Rythm Health panel. Readers should not assume that a broad description of hormone testing identifies every measurement included in a package.
These constraints lead to practical questions for the testing service and the clinician who may use the result:
These questions separate three issues that marketing can blend together: ease of collection, laboratory performance and medical interpretation. A satisfactory answer about convenience does not automatically answer the other two.
They also keep the comparison focused on the actual test. The useful choice is not between assuming that all home testing is unreliable and assuming that all laboratory measurements are interchangeable. It is understanding whether a particular testing pathway is suitable for its intended purpose.
The report does not justify changing diagnostic criteria or starting testosterone treatment on the basis of one home result. Its immediate significance is expanded access to sample collection. The Endocrine Society’s requirements for symptoms and consistently low testosterone remain the relevant clinical framework.
An unexpected or low home result belongs in a discussion with a qualified clinician. That discussion can address the symptoms involved and the test method used. It can also establish whether repeat morning testing is needed and whether the assay and sample type fit the decision being considered.
For men concerned about possible low testosterone, the result should contribute to an assessment rather than substitute for one. Testostra’s guide to how symptoms fit alongside blood testing provides further educational context. A collection device does not determine whether testosterone explains a person’s concerns.
The bottom line is a distinction between access and evidence. Collecting blood at home may make a morning sample more convenient. Whether that result should influence diagnosis or treatment remains a clinical judgment based on the measurement and the wider assessment.
Selecting a home blood collection option leaves the meaning of symptoms unresolved, and Testostra provides evidence-led education around that distinction. Its coverage of low testosterone and emerging research addresses uncertainty about possible causes of symptoms, giving men clearer context for a clinical conversation without offering an individual diagnosis.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra